SKB500
Phase 2Small molecule
SKB500 is one of 46 small molecule programs targeting Small Cell Lung Cancer. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
598 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Tecentriq
RochePhase 3
Gemzar
Johnson & JohnsonPhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Vepesid
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer1 trial
SKB500 Combinations in Patients With Small Cell Lung Cancer
Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07296809·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SKB500. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details